Novel AI algorithm improves decoding accuracy of brain signals
A new deep-learning method could enhance therapeutic devices for people with neurological or mental health conditions.
List view / Grid view
A new deep-learning method could enhance therapeutic devices for people with neurological or mental health conditions.
Using phosphoproteomics, the calcium channel Cav2.3 was found as a target to treat a type of genetic epilepsy, CDKL5 deficiency disorder.
LNPs deliver small interfering RNA to the brain’s microglia to combat inflammation related to Alzheimer’s disease.
By fusing antigen proteins into an anchor protein, a specific disease could be targeted without the need to purify the antigen.
Glioblastomas can resist immunotherapy as perivascular fibroblasts support the creation of an immunosuppressive tumour environment.
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
A discovery about Zika’s enzyme, NS2B-NS3, offers promise for therapeutic targets for Zika and other flaviviruses.
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
Astrocyte plasticity is correlated with upregulation of the Galectin 3 protein, which may greatly contribute to biomarker discovery.
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
Increasing microRNA-22 overexpression in a gene therapy approach treated HCC in mice, offering promise for its prevention and treatment.
A discovery about the mutated protein DECTIN-1, that limits the production of T regulatory cells, could lead to more effective drugs.
A previously unknown process by which pathogens breach immune defences offers promise for treating infectious diseases.
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.